Dr. Liu continued, “The Zhejiang provincial government has ceased to accept applications for such wholesale drug licenses. The acquisition should greatly improve the long-term efficiency of the Company’s supply-chain operation and reduce its supply costs.”
“Looking forward, we will continue our expansion in Zhejiang and Shanghai. We will also continue to expand our online drug store, the only licensed one in Zhejiang, to drive new growth and build long-term shareholder value.”
Second Quarter Results
Revenue increased 42% to $22.2 million for the second quarter, primarily as a result of the same store sale growth, sale from new stores opened within a year and wholesale revenue from Jiuxin Medicine.Same store sales increased 7.7% during the quarter, mainly due to sales of pharmaceutical products covered by government-sponsored medical insurance programs. Revenue also increased from operating additional stores. As of September 30, 2011, the company operated 58 stores, compared with 46 stores a year earlier. Gross profit increased 42% to $6.3 million for the second quarter. Gross margin increased slightly from 28.1% to 28.2%, offset by the lower gross margin from Jiuxin Medicine’s wholesale activities. Selling expenses increased to $2.7 million from $1.2 million, primarily a result of operating 58 store locations, compared with 46 a year earlier. General and administrative expenses for the quarter increased to $1.3 million from $0.8 million, mainly due to addition of new subsidiaries and expenses of being a U.S. public company. Net income attributable to controlling interest for the quarter rose to $1.634 million from $1.627 million. Basic and Diluted earnings per share attributable to controlling interest remained constant at $0.12 a share Six-Month Results Revenue for the six months ended September 30, 2011 increased 41.3% to $43.7 million compared with $30.9 million in the year ago period. Same store sales increased 20.6% from a year earlier, mainly due to sales of pharmaceutical products covered by government-sponsored medical insurance programs. Revenue also increased from operating additional stores.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV